CD4 and malaria: These results suggest that the Pfs25-EPA and Pfs25-TT conjugate vaccines contain CD4+ T cell epitopes that, when formulated with a strong adjuvant like GLA-LSQ, enhance humoral immunity compensating for the deficiency in T epitopes in the malaria antigen itself.